Sandostatin LAR Depot

Novartis Pharmaceuticals Corporation🇺🇸 United States

FDA Page

Effective Date: Dec 22, 2025
Approval ID: d0b7fe9e-7000-4b79-ba3b-291ce92c14f9
Products: 3 registered
Version: 24

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use SANDOSTATIN LAR DEPOT safely and effectively. See full prescribing information for SANDOSTATIN LAR DEPOT. SANDOSTATIN LAR DEPOT (octreotide acetate) for injectable suspension, for gluteal intramuscular use Initial U.S. Approval: 1988

Quick Stats

Total Products3

Labelers2

Label Sections36

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.